drugset / Trial / NCT03979066
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20 given before and after surgery, followed by chemotherapy is safe and if it can further increase the immune response against the tumor rather than increase the chance of cure.
Timeline
- Start
- 2019-11-01
- Primary completion
- 2019-11-03
- Completion
- 2019-11-03
Outcome
Outcome not reported
Stopped (Business): “Loss of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | Intravenous |
| Subject | PEGPH20 | Protein / enzyme biologic | 3 ug/kg | Intravenous |